Back to Newsroom

Conatus Pharmaceuticals Announces Acceptance of Abstracts for AASLD Annual Meeting

SAN DIEGO, Oct. 1, 2015 (GLOBE NEWSWIRE) — Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) announced today that abstracts for two posters addressing preclinical results with the company’s pan-caspase inhibitors, have been accepted for presentation at The Liver Meeting®, the annual meeting of the American Association for the Study of Liver Diseases (AASLD) in San Francisco November 13-17, 2015.

Click here to read more